Eli Lilly and Company Stock News

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients.

Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.

It's increasingly clear that broad bets on healthcare don't make sense as a refuge from the market chaos.

Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.

Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.

Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.

Just like the rest of the stock market, pharmaceutical stocks are in a funk approaching the midweek mark, and it's looking like things might be about to get even worse for this particular pocket of the stock market. On Wednesday, Reuters reported that President Donald Trump is preparing to unveil a new series of tariffs on pharmaceutical imports.

As everyone who follows equity markets knows, stocks are feeling the heat from President Donald Trump's macroeconomic policies. On April 3, the president announced sweeping tariffs on goods imported into the U.S. from basically every country on planet Earth.